Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete response rulings by the agency which require more information before an approval can be granted.

Allos Therapeutics [ALTH: 7.19, -0.13 (-1.78%)]: On 5/30/09 , ALTH updated data from the Company’s pivotal Phase 2 PROPEL study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The overall response rate for pralatrexate as evaluated by central independent

...

US regulators are probing the hiring practices of large Silicon Valley players such as Apple Inc. (AAPL), Google Inc. (GOOG) and Yahoo Inc. (YHOO) to make sure they do not pilfer top talents from their rivals.

Google and Apple have already come under the Federal Trade Commission's scrutiny for the overlap of directors on their boards. The two companies shared Google Chief Executive Eric Schmidt. Again Art Levinson, the former chief of Genentech Inc. (DNA) also sat on Google's board.

However, such collusion in hiring is not uncommon in the technology sector. Microsoft Corp. (MSFT) has accused Google for poaching its executives in the past. Earlier this year, IBM (IBM) sued Apple for swiping away its Vice President Mark Papermaster.

"AAPL" Free Stock Analysis: Buy? Sell? Hold?"GOOG" Free Stock Analysis: Buy? Sell? Hold?"YHOO" Free Stock Analysis: Buy? ...

Today we are featuring top-performing "Flexible" balanced mutual funds, which primarily seek income or total return and can invest in stocks, bonds, or cash without limitation.

Investors can find such funds by checking out the entire list of the Zacks #1 Rank Flexible Balanced Funds.

3 Fine Samples

Changing Parameters (CPMPX) seeks total return. The fund invests primarily in futures contracts, options on futures contracts, swap contracts, exchange-traded funds ("ETFs") and U.S. Treasury instruments.

The fund is non-diversified. It typically invests in U.S. Treasuries with maturities of any duration, or their derivatives, and the allocation of its investments between equity and fixed income market segments may vary without limitation.

Robert Levenson has been lead manager at the fund since October 2006. The fund has outperformed the total returns of its benchmark index in the last 1-year period.

Gabelli ABC (GABCX) was incepted

...

Against the backdrop of a possible launch of Microsoft Corp.'s (MSFT) new smartphone, federal regulators are now investigating if an overlap of directors on the boards of Apple Inc. (AAPL) and Google Inc. (GOOG) breach antitrust laws.

The Silicon Valley giants share two directors on their boards, Eric Schmidt, chief executive of Google, and Arthur Levinson, former chief executive of Genentech Inc. (DNA). The U.S. Federal Trade Commission is examining if such connections thwart market competition in software and services.

Under federal antitrust law, "interlocking directorates" is not allowed if it decreases competition between two companies in the same sector. This law, or the Clayton act, is seldom used and difficult to enforce. The typical outcome of violation under the act would be resignation of the concerned directors from one of the boards.

While Schmidt has been on Google's

...

Today we are featuring top-performing "Health" equity mutual funds, which primarily invest in equity securities of healthcare and related companies.

Investors can find such funds by checking out the entire list of the Zacks #1 Rank Health Equity Funds list.

3 Healthy Picks

Morgan Stanley Health Sciences A (HCRAX) seeks capital appreciation. The fund normally invests at least 80% of assets in common stocks (including depositary receipts) of health science companies throughout the world.

Michael Nolan has been the lead manager at the fund since June 2008. The fund has an expense ratio of 1.50%. It distributes dividends annually.

The fund's top holdings include Johnson & Johnson (JNJ), Pfizer Inc. (PFE) and Merck & Co. Inc. (MRK).

Fidelity Advisor Health Care A (FACDX) was incepted in September 1996 and seeks capital appreciation. It is non-diversified.

...

Highlights include Pfizer Inc. (PFE), Wyeth Pharmaceuticals (WYE), Merck & Co. (MRK) and Schering-Plough (SGP).The freefall in the equity market over the last several months has shifted investor sentiment to higher quality, lower risk investments. The flight to quality resulted in government bond prices spiking as investors sacrificed yield for safety. High quality corporate bonds were largely shunned in favor of risk-free government debt.However, as of late investors have shown significant interest in new high-quality bond offerings, especially those of drug companies. Investors' appetite for drug company bonds has been voracious this year. According to Bloomberg, pharmaceutical companies have sold over $40 billion worth of bonds so far in 2009, compared to only $13 billion for all of 2008.With balance sheets flush with cash and credit ratings in the upper bands of investment grade, pharmaceutical company bonds have become ...

Highlights include Roche Holding Ltd. (RHHBY) and Genentech Inc. (DNA) Merck & Co. (MRK) and Shering-Plough Corp. (SGP).Genentech & Roche Coming to TermsThe Wall Street Journal is reporting that Roche (RHHBY) and Genentech (DNA) are nearing a deal to sign a definitive merger agreement whereby Roche will pay $95 per share for Genentech. The deal would value Genentech at $101 billion total. By comparison, based on today's trading, the combined Merck (MRK) and Shering-Plough (SGP) entity would have a combined market value of $78 billion.The reported $95 per share price is $2 above the $93 offer that came from Roche last week. This is also far above the $86.50 tender offer than Roche announced earlier in the year, and $6 above the original $89 per share bid that was initiated late in 2008. The $95 ...

Roche Raises Genentech Bid to $93/ShareA few minutes ago, Roche Holding Ltd. (RHHBY) announced that it has increased its offer price for all outstanding publicly-held shares of Genentech, Inc. (DNA) to $93 per share, as well as extending the offer to 12:00 midnight EST on Friday, March 20, 2009.All other terms and conditions of the tender offer remain unchanged. The new offer just released is up $6.50 per share and values Genentech vale at approximately $100 billion total. By comparison, Pfizer Ltd. (PFE) has a market value of approximately $85 billion.Roche is raising its bid based on the poor turnout of the tender offer so far. As of March 5, 2009, Roche noted only approximately 500,000 shares have been tendered at the $86.50 previous offer. Roche currently own roughly 57% of the outstanding shares and needs to acquire at least ...

Genentech (DNA) posted solid results for the fourth quarter and full year 2008. Sales of Avastin and Rituxan grew double digits in 2008 and the company saw non-GAAP earnings rise by 16%.

Growth in 2009 will not come as easily however. Rituxan is slowing and much of Avastin s future upside potential is based on expanding the label into new areas of growth including glioblastoma, renal cell carcinoma, and adjuvant colon cancer.

Under normal circumstances, we might call 2009 a transition year. But Roche s $89/share bid is still on the table, and speculation is increasing that an even higher bid is coming. Genentech s standalone value is between $90 and $95 per share based on our financial forecasts. However, a new bid from Roche could push the shares closer to $100. Therefore, we recommend continuing to own the name. Downside seems limited as long as

...

Genentech, Inc. (...